Jul 12, 2021 07:35 PM IST
Net Sales are expected to increase by 13.4 percent Y-o-Y (up 3.1 percent Q-o-Q) to Rs 1,895.3 crore, according to ICICI Direct.
- Apr 12, 2021 08:40 PM IST
Net Sales are expected to increase by 28.3 percent Y-o-Y (up 8 percent Q-o-Q) to Rs. 1,999.6 crore, according to Sharekhan.
- Jan 18, 2021 07:58 PM IST
Net Sales are expected to increase by 15.4 percent Y-o-Y (up 15.7 percent Q-o-Q) to Rs. 2,018.1 crore, according to ICICI Direct.
- Apr 17, 2019 03:12 PM IST
Net Sales are expected to increase by 31.6 percent Y-o-Y (down 0.1 percent Q-o-Q) to Rs. 1,538.7 crore, according to Kotak.
- Jan 18, 2019 02:58 PM IST
Net Sales are expected to increase by 32.4 percent Y-o-Y (up 6 percent Q-o-Q) to Rs. 1,400.7 crore, according to Sharekhan.
- Jan 11, 2019 05:26 PM IST
Net Sales are expected to increase by 30.7 percent Y-o-Y (up 4.6 percent Q-o-Q) to Rs. 1,382.4 crore, according to ICICI Direct.
- Oct 27, 2018 08:00 AM IST
“We expect momentum in the Biologics segment to continue with new market launches expected later in the year and increase penetrations in markets where our products have already been commercialized,” said Kiran Mazumdar-Shaw, Chairperson and Managing Director of Biocon to analysts.
- Oct 16, 2018 07:22 PM IST
Net Sales are expected to increase by 19.1 percent Y-o-Y (up 2.7 percent Q-o-Q) to Rs. 1,154 crore, according to Sharekhan.
- Oct 12, 2018 04:07 PM IST
Net Sales are expected to increase by 28.6 percent Y-o-Y (up 10.8 percent Q-o-Q) to Rs. 1,245.4 crore, according to ICICI Direct.
- Jul 18, 2018 02:08 PM IST
Net Sales are expected to increase by 24.4 percent Y-o-Y (down 0.6 percent Q-o-Q) to Rs. 1,162 crore, according to Kotak.
- Jan 25, 2018 12:57 PM IST
We are going to expand our biosimilars pipeline both with Mylan and Sandoz and beyond on our own, said Kiran Mazumdar Shaw, CMD, Biocon.
- Jan 24, 2018 02:19 PM IST
EBITDA Margins around 31-33% with focus on growth and investments are good, said Jonathan Hunt, CEO of Syngene International.
- Oct 27, 2017 12:53 PM IST
In an interview to CNBC-TV18, Kiran Mazumdar Shaw, Chairperson & MD of Biocon spoke about the results and her outlook for the company.
- Oct 13, 2017 05:40 PM IST
Net Sales are expected to increase by 8.4 percent Y-o-Y (up 9.1 percent Q-o-Q) to Rs. 1018.9 crore, according to Kotak.
- Jul 28, 2017 11:37 AM IST
In an interview to CNBC-TV18, Amey Chalke of HDFC Securities spoke about Q1 FY18 earnings from pharma sector.
- Jul 27, 2017 11:24 AM IST
Operating profit during the quarter may drop 20% to Rs 211.3 crore and margin may contract by 560 basis points to 21.2 percent year-on-year.
- Apr 28, 2017 07:56 PM IST
Biocon chairperson Kiran Mazumdar-Shaw told Moneycontrol that the company is focusing on ramping up its biologics business, which accounts for 15 percent of overall revenues, but has the potential to be a game changer.
- Apr 26, 2017 06:37 PM IST
Operating profit is expected to jump 20 percent year-on-year to Rs 254.4 crore and margin may expand 240 basis points to 23.5 percent in the quarter ended March 2017.
- Jan 25, 2017 11:02 AM IST
Attributing the strong show in Q3FY17 to robust performance in biologics, Biocon Chairperson and MD Kiran Mazumdar-Shaw told CNBC-TV18 that Biocon is well poised to be front-runner in biosimilars. The acceptance of biosimilar Trastuzumab by the USFDA is a huge milestone for Mylan and Biocon, she said.
- Jan 24, 2017 08:42 AM IST
Biopharmaceutical company Biocon's third quarter profit is likely to increase 38 percent year-on-year to Rs 142 crore and revenue may grow 15.5 percent to Rs 965.7 crore.
- Oct 21, 2016 11:56 AM IST
Biotechnology major Biocon reported 19.8 percent rise in revenue to Rs 796.2 crore year-on-year and margins grew to 25.2 percent from 21.2 percent in the second quarter of FY17. The company‘s standalones sale grew 17 percent in Q2.
- Oct 19, 2016 05:12 PM IST
Biocon's profit is expected to fall 55 percent to Rs 137.2 crore in July-September quarter compared with Rs 305.9 crore in year-ago period, according to average of estimates of analysts polled by CNBC-TV18.
- Oct 19, 2016 03:08 PM IST
Net Sales are expected to increase by 3.5 percent Q-o-Q (up 21.5 percent Y-o-Y) to Rs 1017 crore, according to Centrum.
- Jul 22, 2016 01:13 PM IST
Of USD 200 million capex, USD 100 million will go into four key areas- Syngene Research Centre, biologic centre, formulation center, viral testing and the rest in commercial manufacturing, says Jonathan Hunt, CEO of Syngene International.
- Jul 22, 2016 12:58 PM IST
The most important news that everyone will be tracking is when we submit dossiers in Europe and US for insulin Glargine and that as we have indicated will happen this fiscal, says Kiran Mazumdar Shaw